Blueprint Medicines Corporation
BPMCN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
1
Next Catalyst
Q4 2026
Market Overview
Stock performance and key metrics
BPMC News
Catalyst Timeline
1 upcoming, 0 past
Drug Pipeline
regorafenib
GIST
Elenestinib
Indolent Systemic Mastocytosis
avapritinib
Solid Tumor, Unspecified, Child
BLU-808
Chronic Inducible Urticaria
BLU-924
Advanced Solid Tumor
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
regorafenib | Phase 3 | GIST | - | - |
Elenestinib | Phase 3 | Indolent Systemic Mastocytosis | - | - |
avapritinib | Phase 3 | Solid Tumor, Unspecified, Child | - | - |
BLU-808 | Phase 2 | Chronic Inducible Urticaria | - | - |
BLU-924 | Phase 2 | Advanced Solid Tumor | - | - |
Indolent Systemic Mastocytosis
2 drugs in this indication
GIST
1 drug in this indication
Solid Tumor, Unspecified, Child
1 drug in this indication
Chronic Inducible Urticaria
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Catalyst Verdict
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply